Susquehanna Fundamental Investments LLC Invests $23.52 Million in DexCom, Inc. (NASDAQ:DXCM)

Susquehanna Fundamental Investments LLC acquired a new position in DexCom, Inc. (NASDAQ:DXCM - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 302,458 shares of the medical device company's stock, valued at approximately $23,522,000. Susquehanna Fundamental Investments LLC owned 0.08% of DexCom as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the company. Versant Capital Management Inc acquired a new stake in DexCom during the 4th quarter valued at $25,000. Private Trust Co. NA boosted its holdings in DexCom by 266.3% during the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock valued at $26,000 after acquiring an additional 245 shares during the period. TD Private Client Wealth LLC boosted its holdings in DexCom by 62.8% during the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock valued at $34,000 after acquiring an additional 167 shares during the period. Larson Financial Group LLC boosted its holdings in DexCom by 40.5% during the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock valued at $37,000 after acquiring an additional 137 shares during the period. Finally, Heck Capital Advisors LLC bought a new stake in DexCom during the fourth quarter valued at about $38,000. Institutional investors and hedge funds own 97.75% of the company's stock.

Insider Activity at DexCom

In related news, CEO Kevin R. Sayer sold 33,359 shares of the company's stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $2,899,230.69. Following the completion of the sale, the chief executive officer now owns 319,037 shares in the company, valued at approximately $27,727,505.67. This represents a 9.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, COO Jacob Steven Leach sold 2,634 shares of the stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the completion of the sale, the chief operating officer now owns 268,644 shares of the company's stock, valued at $23,347,850.04. This trade represents a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 105,009 shares of company stock worth $8,044,178. 0.32% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on DXCM shares. Wells Fargo & Company reaffirmed an "overweight" rating on shares of DexCom in a research report on Saturday, March 8th. Canaccord Genuity Group boosted their price target on DexCom from $99.00 to $103.00 and gave the company a "buy" rating in a research note on Friday, February 14th. Morgan Stanley boosted their price objective on DexCom from $75.00 to $82.00 and gave the stock an "equal weight" rating in a research note on Friday, February 14th. Mizuho assumed coverage on DexCom in a research note on Thursday, April 10th. They issued an "outperform" rating and a $85.00 price objective on the stock. Finally, Citigroup boosted their price objective on DexCom from $101.00 to $104.00 and gave the stock a "buy" rating in a research note on Tuesday, March 4th. Five analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $99.00.

DexCom Trading Up 0.2 %

Shares of DXCM traded up $0.12 during trading hours on Tuesday, hitting $71.30. 2,331,956 shares of the stock traded hands, compared to its average volume of 4,207,837. The business has a fifty day moving average of $72.72 and a 200-day moving average of $76.74. The firm has a market capitalization of $27.96 billion, a PE ratio of 49.86, a price-to-earnings-growth ratio of 2.30 and a beta of 1.50. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. DexCom, Inc. has a 1-year low of $57.52 and a 1-year high of $132.26.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Analysts expect that DexCom, Inc. will post 2.03 EPS for the current year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.